Business, energy, technology, markets and global industry news from Business News Today

ophthalmology

PharmaDeviceNews ophthalmology
Representative image: An ophthalmic surgeon performs cataract surgery, reflecting ZEISS Medical Technology’s AT LUCIA toric 721P lens and the growing focus on precision intraocular lenses for astigmatism correction.
Medical Devices & Diagnostics

Could ZEISS’s new toric intraocular lens improve predictability in astigmatism correction?

Find out how ZEISS’s AT LUCIA toric 721P lens could improve cataract surgery precision and astigmatism correction.

Read More
Representative image showing retinal eye care and injectable ophthalmology treatment as Samsung Bioepis expands Europe’s aflibercept biosimilar market with the launch of OPUVIZ for major retinal diseases.
Pharma & Biotech

Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Read More
Pharma & Biotech

Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?

Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.

Read More
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More
Representative image of a modern ophthalmology research setting showing tablet-based contrast sensitivity testing, reflecting PerZeption Inc.’s AIM+ CSF collaboration with Alcon Research to advance faster digital vision assessment.
Medical Devices & Diagnostics

Can PerZeption and Alcon make contrast sensitivity testing faster for vision correction research?

Vision testing is getting faster. PerZeption and Alcon now face the harder test: proving AIM+ CSF can reshape research-grade evidence.

Read More
Representative image: Ophthalmology researchers evaluate retinal imaging data as Spinogenix’s tazbentetol preclinical results raise new questions about synaptic regeneration, glaucoma neuroprotection, and diabetic retinopathy treatment strategies.
Pharma & Biotech

Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research

Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.

Read More
Representative image: A retina specialist prepares an office-based ocular injection, reflecting Everads Therapy’s push to advance suprachoroidal drug delivery for diabetic macular edema and other retinal diseases.
Medical Devices & Diagnostics

Can Everads Injector change how ophthalmology drugs reach the back of the eye?

Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.

Read More
Representative image: A child undergoing an eye examination in a modern ophthalmology clinic, reflecting Sydnexis’ Phase 3 SYD-101 data focus on low-dose atropine treatment for fast-progressing pediatric myopia.
Pharma & Biotech

Can Sydnexis’ SYD-101 data sharpen the case for low-dose atropine in fast-progressing pediatric myopia?

Pediatric myopia is rising fast, but U.S. drug options remain thin. Sydnexis’ SYD-101 data may sharpen the regulatory race.

Read More
Pharma & Biotech

What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement

Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.

Read More
Representative image of cataract surgery with an intraocular lens, used to illustrate Johnson & Johnson’s TECNIS PureSee data at ASCRS 2026 and the shifting premium IOL market.
Medical Devices & Diagnostics

Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?

Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.

Read More